About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

56.33 +0.66 (+1.18%)
Streaming Delayed Price Updated: 10:50 AM EDT, May 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
89 90 Next >
News headline image
Bristol-Myers Squibb (BMY): Buy, Sell, or Hold Post Q1 Earnings?
Bristol-Myers Squibb has had an impressive run over the past six months as its shares have beaten the S&P 500 by 5.7%. The stock now trades at $55.77, markin... 
Via StockStory
Topics Stocks
News headline image
Is Bristol Myers Squibb Stock Overvalued at Nearly $60? A Reality Check for Value Investors. ↗
This may be an excellent deal for those focused on the long game. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Bristol Myers Squibb Touts Pipeline Gains as Shareholders Back Board at Annual Meeting ↗
Bristol Myers Squibb (NYSE:BMY) used its 2026 annual meeting of shareholders to highlight progress in its growth portfolio, pipeline development, balance sheet management and cost-saving initiatives,... 
Via MarketBeat
Bristol Myers Squibb (NYSE:BMY) Q1 2026 Earnings Beat Driven by Growth Portfolio ↗
Via Chartmill
Topics Earnings
News headline image
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol-Myers Squibb’s Q1 Earnings Call: Our Top 5 Analyst Questions
Bristol-Myers Squibb’s first quarter results were notably shaped by ongoing momentum in its growth portfolio and steady execution across key marketed product... 
Via StockStory
Topics Earnings
News headline image
Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026
From Bristol Myers Squibb
Via Business Wire
News headline image
1 Healthcare Stock with Competitive Advantages and 2 Facing Challenges
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged... 
Via StockStory
News headline image
Bristol Myers Squibb Launches “Won't Lose” Media Campaign Ahead of FIFA World Cup 2026™
From Bristol Myers Squibb
Via Business Wire
News headline image
BMY Q1 Deep Dive: Growth Portfolio, Pipeline Milestones, and Anticipated Late-Stage Readouts
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q1 CY2026, with sales up 2.6% year on year to $11.49 bill... 
Via StockStory
News headline image
Why Bristol Myers Squibb Stock Rocked the Market Today ↗
It scored crushing beats on both revenue and profitability in its first quarter. 
Via The Motley Fool
News headline image
Bristol Myers (BMY) Q1 2026 Earnings Transcript ↗
Bristol Myers (BMY) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Bristol-Myers Squibb (NYSE:BMY) Exceeds Q1 CY2026 Expectations
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced better-than-expected revenue in Q1 CY2026, with sales up 2.6% year on year to $11.49 bill... 
Via StockStory
News headline image
Bristol Myers Squibb Reports First Quarter Financial Results for 2026
From Bristol Myers Squibb
Via Business Wire
News headline image
Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q1 Results Tomorrow
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting earnings this Thursday before market open. Here’s what investors should know. Bri... 
Via StockStory
News headline image
3 Healthcare Stocks That Pay You While You Wait for the Growth ↗
It may not seem like it at first, but these dividends are safe. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Biotech Stocks That Could Benefit from the Patent Cliff ↗
Via MarketBeat
Topics Intellectual Property
News headline image
Is Bristol Myers Squibb the Best Bargain in Big Pharma? ↗
This pharma stock is cheap for a reason. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Bristol Myers Squibb: Low Volatility Meets High Dividend Yield ↗
Volatility and dividend yield are important metrics for investors thinking about a long-term buy. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Healthcare Stocks That Pay You a Dividend While You Wait for a Recovery ↗
As you wait for stock prices to rebound, these three healthcare companies pay dividends with generous yields. 
Via The Motley Fool
Topics Intellectual Property World Trade
News headline image
1 Unpopular Stock That Should Get More Attention and 2 We Question
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t... 
Via StockStory
News headline image
Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
2 Healthcare Stocks to Buy and 1 to Approach With Caution ↗
Recent performances don't tell the whole story. 
Via The Motley Fool
News headline image
J&J Shatters Estimates as Oncology and MedTech Power 2026 Outlook Higher
Johnson & Johnson (NYSE: JNJ) delivered a robust first-quarter 2026 earnings report on April 14, 2026, handily beating Wall Street expectations and signaling a successful navigation of the long-feared... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
The RAS Revolution: A Deep Dive into Revolution Medicines’ Path to Dominance (2026 Report)
As of today, April 14, 2026, the biotechnology landscape is being reshaped by a singular clinical milestone that many once deemed impossible. Just twenty-four hours ago, Revolution Medicines, Inc.... 
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
Which Dividend Pharma Stock Should a Value Investor Choose Today? ↗
Bristol Myers Squibb looks like a value buy, so long as its pipeline remains strong. 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Recession Resistant Dividend Stocks to Buy Now While They're Still Cheap ↗
Healthcare never sleeps. 
Via The Motley Fool
Topics Economy Intellectual Property
News headline image
Neurocrine Biosciences (NBIX): A New Era in Neuroscience and Endocrinology
Date: April 7, 2026 Introduction Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has long been a bellwether for the mid-cap biotechnology sector, serving as a primary case study in how a company can... 
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
Lilly’s $47.8 Billion Bet: Why the Contessa Acquisition Redefines the Future of Medicine
In a move that has sent shockwaves through both the pharmaceutical and technology sectors, Eli Lilly and Company (NYSE: LLY) announced today, April 6, 2026, the finalized acquisition of Contessa, a... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
Gilead Extends Tender Offer for Arcellx as Biotech M&A Sentiment Faces a Reality Check
Gilead Sciences (NASDAQ: GILD) announced a strategic extension of its tender offer to acquire cell therapy innovator Arcellx (NASDAQ: ACLX) on April 1, 2026. Originally scheduled to expire on April 2,... 
Via MarketMinute
< Previous 1 2 3 4 5 6 7 8 9
...
89 90 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.